Biomarkers for Drug-Induced Kidney Injury Receive Boost From EMA, FDA

Drug Industry Daily
A A
The European Medicines Agency has lent its support to an initiative to qualify biomarkers that can provide an early warning on an investigational compound’s risks of causing drug-induced kidney injuries, an endorsement that researchers say is necessary to move to the next phase of development.

To View This Article:

Login

Subscribe To Drug Industry Daily